DK2280952T3 - Thienopyridinonderivater som amp-aktiverede proteinkinase(ampk)aktivatorer - Google Patents

Thienopyridinonderivater som amp-aktiverede proteinkinase(ampk)aktivatorer

Info

Publication number
DK2280952T3
DK2280952T3 DK09741799.2T DK09741799T DK2280952T3 DK 2280952 T3 DK2280952 T3 DK 2280952T3 DK 09741799 T DK09741799 T DK 09741799T DK 2280952 T3 DK2280952 T3 DK 2280952T3
Authority
DK
Denmark
Prior art keywords
thienopyridino
ampk
activators
derivatives
protein kinase
Prior art date
Application number
DK09741799.2T
Other languages
Danish (da)
English (en)
Inventor
Daniel Cravo
Franck Lepifre
Sophie Hallakou-Bozec
Christine Charon
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40756916&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2280952(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Application granted granted Critical
Publication of DK2280952T3 publication Critical patent/DK2280952T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
DK09741799.2T 2008-05-05 2009-04-08 Thienopyridinonderivater som amp-aktiverede proteinkinase(ampk)aktivatorer DK2280952T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290423 2008-05-05
PCT/EP2009/002606 WO2009135580A1 (en) 2008-05-05 2009-04-08 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Publications (1)

Publication Number Publication Date
DK2280952T3 true DK2280952T3 (da) 2012-07-23

Family

ID=40756916

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09741799.2T DK2280952T3 (da) 2008-05-05 2009-04-08 Thienopyridinonderivater som amp-aktiverede proteinkinase(ampk)aktivatorer

Country Status (26)

Country Link
US (1) US8604202B2 (cg-RX-API-DMAC7.html)
EP (1) EP2280952B1 (cg-RX-API-DMAC7.html)
JP (1) JP5536757B2 (cg-RX-API-DMAC7.html)
KR (2) KR20160038065A (cg-RX-API-DMAC7.html)
CN (1) CN102015676B (cg-RX-API-DMAC7.html)
AR (1) AR071530A1 (cg-RX-API-DMAC7.html)
AU (1) AU2009243811B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0910832B8 (cg-RX-API-DMAC7.html)
CA (1) CA2723429C (cg-RX-API-DMAC7.html)
CO (1) CO6331304A2 (cg-RX-API-DMAC7.html)
CY (1) CY1113112T1 (cg-RX-API-DMAC7.html)
DK (1) DK2280952T3 (cg-RX-API-DMAC7.html)
EA (1) EA020773B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP10010654A (cg-RX-API-DMAC7.html)
ES (1) ES2388485T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20120549T1 (cg-RX-API-DMAC7.html)
IL (1) IL208988A (cg-RX-API-DMAC7.html)
MX (1) MX2010011916A (cg-RX-API-DMAC7.html)
MY (1) MY160357A (cg-RX-API-DMAC7.html)
NZ (1) NZ589690A (cg-RX-API-DMAC7.html)
PL (1) PL2280952T3 (cg-RX-API-DMAC7.html)
PT (1) PT2280952E (cg-RX-API-DMAC7.html)
SI (1) SI2280952T1 (cg-RX-API-DMAC7.html)
UA (1) UA103617C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009135580A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201008722B (cg-RX-API-DMAC7.html)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2552435A1 (en) 2010-04-02 2013-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5990170B2 (ja) * 2010-09-01 2016-09-07 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 除草活性を有するケトスルタム類及びジケトピリジン類
EP2683690A1 (en) * 2011-03-07 2014-01-15 GlaxoSmithKline LLC Quinolinone derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2679591A1 (en) 2012-06-29 2014-01-01 Poxel Thienopyridone derivatives useful as activators of AMPK
EP2970177A1 (en) 2013-03-15 2016-01-20 Pfizer Inc. Indole compounds that activate ampk
WO2015103480A1 (en) 2014-01-02 2015-07-09 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
WO2015114663A1 (en) 2014-01-30 2015-08-06 Council Of Scientific & Industrial Research Novel thieno [2,3-d]pyrimidin-4(3h)-one compounds with antimycobacterial properties
US10308663B2 (en) 2015-06-16 2019-06-04 University Of Virginia Patent Foundation Inhibitors of PTP4A3 for the treatment of cancer
MA42456B1 (fr) 2015-06-25 2021-06-30 Univ Health Network Inhibiteurs de hpk1 et leurs procédés d'utilisation
US20190054096A1 (en) 2015-09-30 2019-02-21 Instituto De Medicina Molecular Methods for attenuating parasite virulence
WO2019067442A1 (en) * 2017-09-26 2019-04-04 Ideaya Biosciences, Inc. DIHYDROTHIENO [3,2-B] PYRIDINE COMPOUNDS
WO2019106087A1 (en) * 2017-11-29 2019-06-06 Syddansk Universitet Ampk inhibitors
WO2021236617A1 (en) 2020-05-19 2021-11-25 Kallyope, Inc. Ampk activators
CN116390925A (zh) 2020-06-26 2023-07-04 卡尔优普公司 Ampk活化剂
EP4221700A1 (en) 2020-09-30 2023-08-09 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
WO2022106892A1 (en) 2020-11-17 2022-05-27 Instituto De Medicina Molecular Anti-malarial compounds
JP2024540522A (ja) 2021-11-19 2024-10-31 ザ・ブロード・インスティテュート・インコーポレイテッド キナーゼを標的結合部分で標識するための二官能性キメラ分子及びその使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8627698D0 (en) * 1986-11-20 1986-12-17 Boots Co Plc Therapeutic agents
DE4444815A1 (de) * 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
AR040123A1 (es) 2002-05-31 2005-03-16 Upjohn Co Compuestos tiofeno, antihelminticos e insecticidas
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
WO2006093518A2 (en) * 2004-06-25 2006-09-08 Apath, Llc Thienyl compounds for treating virus-related conditions
US7563813B2 (en) * 2005-05-13 2009-07-21 Wyeth Iminothiazolidinone derivatives as SFRP-1 antagonists
EP1754483A1 (en) * 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
AU2006327898A1 (en) * 2005-12-20 2007-06-28 Richter Gedeon Nyrt. New compounds
UA103321C2 (ru) * 2008-04-11 2013-10-10 Мерк Патент Гмбх Производные тиенопиридона как активаторы amp-активированной протеинкиназы (амрк)

Also Published As

Publication number Publication date
CA2723429A1 (en) 2009-11-12
AU2009243811B2 (en) 2014-04-10
KR101648593B1 (ko) 2016-08-16
BRPI0910832B1 (pt) 2020-09-15
CN102015676A (zh) 2011-04-13
ES2388485T3 (es) 2012-10-15
BRPI0910832B8 (pt) 2021-05-25
US20110060001A1 (en) 2011-03-10
JP2011519876A (ja) 2011-07-14
ZA201008722B (en) 2012-01-25
AR071530A1 (es) 2010-06-23
EP2280952B1 (en) 2012-06-27
KR20160038065A (ko) 2016-04-06
PT2280952E (pt) 2012-09-28
MY160357A (en) 2017-02-28
PL2280952T3 (pl) 2012-10-31
NZ589690A (en) 2012-07-27
CN102015676B (zh) 2014-05-28
UA103617C2 (ru) 2013-11-11
WO2009135580A1 (en) 2009-11-12
CA2723429C (en) 2016-10-11
JP5536757B2 (ja) 2014-07-02
IL208988A (en) 2016-02-29
US8604202B2 (en) 2013-12-10
IL208988A0 (en) 2011-01-31
EP2280952A1 (en) 2011-02-09
CO6331304A2 (es) 2011-10-20
AU2009243811A1 (en) 2009-11-12
BRPI0910832A2 (pt) 2015-08-11
EA201001733A1 (ru) 2011-06-30
HK1156313A1 (en) 2012-06-08
HRP20120549T1 (hr) 2012-07-31
BRPI0910832A8 (pt) 2016-07-12
EA020773B1 (ru) 2015-01-30
KR20110010757A (ko) 2011-02-07
MX2010011916A (es) 2010-11-26
CY1113112T1 (el) 2016-04-13
SI2280952T1 (sl) 2012-09-28
ECSP10010654A (es) 2011-01-31

Similar Documents

Publication Publication Date Title
DK2280952T3 (da) Thienopyridinonderivater som amp-aktiverede proteinkinase(ampk)aktivatorer
ZA201008050B (en) Thienopyridone derivatives as amp-activated protein kinase (ampk) activators
DK1926722T3 (da) Substituerede benzimidazoler som kinaseinhibitorer
DK2004654T3 (da) Pyrazolopyrimidin derivater til anvendelse som kinase antagonister
DK2300013T4 (da) Phosphorderivater som kinasehæmmere
DK2220070T3 (da) 2-benzylpyridazinonderivater som Met-kinaseinhibitorer
DK1846394T3 (da) Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer
DK2201012T3 (da) Pyrrolo[2,3-d]pyrimidinderivater som proteinkinase b-hæmmere
LT3354650T (lt) Junginiai, naudingi kaip atr kinazės inhibitoriai
DK2261223T3 (da) Pyrimidinderivater anvendt som PI-3-kinasehæmmere
ATE541850T1 (de) Pyrroloä2,3-cüpyridinderivate als p38-kinase- hemmende mittel
DK2252597T3 (da) Pyrazinderivater og deres anvendelse som proteinkinaseinhibitorer
BRPI0922937A2 (pt) inibidores de pirrolopirazinil uréia quinase
DK2414362T3 (da) Pyrimidinsubstituerede purinforbindelser som kinaseinhibitorer
DK2283024T3 (da) 4-aryl-2-anilinpyrimidiner som PLK-kinaseinhibitorer
DK2125792T3 (da) Purinderivater som immunomodulatorer
BRPI0907928A2 (pt) Inibidores de pirrolopirazina quinase.
BRPI0716477A2 (pt) Derivados heteroarila como inibidores de quinase protéica
DK2513105T3 (da) 2-arylimidazolderivater som pde10a-enzyminhibitorer
DK2195312T3 (da) Pyridinderivater anvendelige som glucokinaseaktivatorer
DK2513107T3 (da) Heteroaromatiske phenylimidazol-derivater som pde10a-enzyminhibitorer
DK2021335T3 (da) Heterocykliske forbindelser som C-FMS-kinasehæmmere
DK2513106T3 (da) Heteroaromatiske aryltriazol-derivater som pde10a-enzyminhibitorer
DK2069310T3 (da) Sulfonylpyrazolin-1-carboxamidin-derivater som 5-HT6-antagonister
BRPI0921509A2 (pt) inibidor triazolotiadiazol de proteína quinase c-met